5309-14-8

Usage

Uses

Used in Organic Synthesis:
4-Cyano-4-(4-methoxyphenyl)cyclohexanone is utilized as a starting material in organic synthesis for the creation of various compounds. Its unique structure allows for the development of a wide range of chemical entities with diverse properties and applications.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4-Cyano-4-(4-methoxyphenyl)cyclohexanone serves as a valuable starting material for the synthesis of new drug candidates. Its potential pharmacological uses make it an attractive compound for researchers working on the development of novel therapeutic agents.
Used as an Anti-inflammatory Agent:
4-Cyano-4-(4-methoxyphenyl)cyclohexanone has demonstrated anti-inflammatory properties, making it a potential candidate for the development of new anti-inflammatory drugs. Its ability to modulate inflammatory processes could provide relief for patients suffering from various inflammatory conditions.
Used in Drug Discovery:
As a potential target for drug discovery, 4-Cyano-4-(4-methoxyphenyl)cyclohexanone offers opportunities for the development of new therapeutic agents with unique mechanisms of action. Its structural features and pharmacological potential make it a promising candidate for further research and development in the field of medicinal chemistry.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-Cyano-4-(4-methoxyphenyl)cyclohexanone is studied for its potential applications in the development of new drugs. Its unique structure and properties provide a foundation for the design and synthesis of novel compounds with potential therapeutic benefits.

InChI:InChI=1/C9H7Cl3N4/c1-4(2)15-16-9-7(11)6(10)5(3-13)8(12)14-9/h1-2H3,(H,14,16)

Upstream product

• 56326-96-6 methyl 5-cyano-5-(4-methoxyphenyl)-2-oxocyclohexanecarboxylate 

Relevant academic research and scientific papers

SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS

The invention relates to substituted isoquinoline and isoquinolinones of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.

DI(HETERO)ARYLCYCLOHEXANE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

The present invention relates to di(hetero)arylcyclohexane derivatives of the formula (I), in which Ar1, Ar2, R1 and R2 have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmaceutical active compounds which inhibit ATP-sensitive potassium channels in the heart muscle and are suitable, for example, for the treatment of disorders of the cardiovascular system such as arrhythmias or a decreased contractility of the heart, such as can occur, for example, in coronary heart disease, cardiac insufficiency or cardiomyopathies. In particular, they are suitable for the prevention of sudden cardiac death. The invention furthermore relates to processes and intermediates for the preparation of the compounds of the formula (I), their use and pharmaceutical compositions comprising them.

4-Arylcyclohexylamines

The invention relates to novel 4-hydroxymethyl(acyloxymethyl and methyl)-4-arylcyclohexylamines embraced by the formula SPC1 Wherein Ar is an aromatic ring selected from the group consisting of phenyl and naphthyl, each of which has from zero through three substituents independently selected from the group consisting of fluorine, chlorine, bromine, lower alkyl of one through three carbon atoms, lower alkoxy of one through three carbon atoms, and lower alkylthio of one through three carbon atoms; Z is selected from the group consisting of hydrogen, hydroxy and lower acyloxy of one through four carbon atoms; ? is a generic expression denoting cis and trans stereoconfiguration and mixtures thereof, with the proviso that when the stereoconfiguration of the linkage connecting the cyclohexane ring and CH2 Z is cis to the amino group, the linkage connecting the cyclohexane and Ar rings is trans, and vice versa; R1 is selected from the group consisting of hydrogen and lower alkyl of one through three carbon atoms; R2 is selected from the group consisting of hydrogen, lower alkyl of one through three carbon atoms, EQU1 WHEREIN N IS 2 THROUGH 5 AND Ar has the same meaning as above; R1 and R2 taken together with --N is a saturated heterocyclic amino radical selected from the group consisting of unsubstituted and substituted pyrrolidino, piperidino, hexamethylenimino, morpholino and piperazino; and pharmacologically acceptable acid addition salts thereof. It also relates to intermediates and processes for the preparation of the aforesaid novel compounds (I) and novel derivatives thereof. The administration to humans and animals of the novel compounds (I) depresses their central nervous systems and lowers their blood pressures.

Butyrophenones as hypotensive agents. Derivatives of 4 aryl 4 (hydroxymethyl)cyclohexylamine

The preparation of butyrophenone derivatives of 4 aryl 4 (hydroxymethyl) cyclohex 1 ylamines starting from the corresponding 4 cyano 4 phenylcyclohexan 1 ones is described. Substitution was varied in both rings; both isomers of 4 phenyl 4 (hydroxymethyl)cyclohex 1 ylamine were characterized. Those derivatives which carried p fluoro substitution on the butyrophenone exhibited hypotensive activity in the rat with diminished CNS activity compared to compounds lacking the hydroxymethyl group. The effect of substitution on the 4 aryl ring is discussed.